MGL RAAMATUPIDAMINE UÜ
Date of report 25.11.2024
Open the reports you want to print
Employees and salaries
MGL RAAMATUPIDAMINE UÜ
Employee taxes and performance analysis?
| Quarter | Labor taxes paid | Number of employees | Turnover Per Employee | Profit per employee |
|---|---|---|---|---|
| 2024 III | ...... | ...... | ...... | ...... |
| 2024 II | ...... | ...... | ...... | ...... |
| 2024 I | ...... | ...... | ...... | ...... |
| 2023 IV | ...... | ...... | ...... | ...... |
| 2023 III | ...... | ...... | ...... | ...... |
| 2023 II | ...... | ...... | ...... | ...... |
| 2023 I | ...... | ...... | ...... | ...... |
| 2022 IV | ...... | ...... | ...... | ...... |
| 2022 III | ...... | ...... | ...... | ...... |
| 2022 II | ...... | ...... | ...... | ...... |
| 2022 I | ...... | ...... | ...... | ...... |
| 2021 IV | ...... | ...... | ...... | ...... |
| 2021 III | ...... | ...... | ...... | ...... |
| 2021 II | ...... | ...... | ...... | ...... |
| 2021 I | ...... | ...... | ...... | ...... |
| 2020 IV | ...... | ...... | ...... | ...... |
| 2020 III | ...... | ...... | ...... | ...... |
| 2020 II | ...... | ...... | ...... | ...... |
| 2020 I | ...... | ...... | ...... | ...... |
| 2019 IV | ...... | ...... | ...... | ...... |
| 2019 III | ...... | ...... | ...... | ...... |
| 2019 II | ...... | ...... | ...... | ...... |
| 2019 I | ...... | ...... | ...... | ...... |
| 2018 IV | ...... | ...... | ...... | ...... |
| 2018 III | ...... | ...... | ...... | ...... |
| 2018 II | ...... | ...... | ...... | ...... |
| 2018 I | ...... | ...... | ...... | ...... |
| 2017 IV | ...... | ...... | ...... | ...... |
| 2017 III | ...... | ...... | ...... | ...... |
| 2017 II | ...... | ...... | ...... | ...... |
| 2017 I | ...... | ...... | ...... | ...... |
| 2016 IV | ...... | ...... | ...... | ...... |
| 2016 III | ...... | ...... | ...... | ...... |
| 2016 II | ...... | ...... | ...... | ...... |
| 2016 I | ...... | ...... | ...... | ...... |
| 2015 IV | ...... | ...... | ...... | ...... |
| 2015 III | ...... | ...... | ...... | ...... |
| 2015 II | ...... | ...... | ...... | ...... |
| 2015 I | ...... | ...... | ...... | ...... |
Deciders and beneficiaries
MGL RAAMATUPIDAMINE UÜ
Deciders?
Former deciders
Relations: 5
Turnover 2024: 65 505 €
Employees: 4
Merlyn Loime
★★★★
......
Credit Score: Borderline
Reputation scores: 1350
Date of birth: ......
Active relations 5
2024 III quarter
Turnover: 11 705 €
Employees: 2
Average salary: 585 €
MGL Disaine OÜ
......
*
MGL RAAMATUPIDAMINE UÜ
Former deciders?
Relations: 1
Turnover:
Employees:
Gert Kuosmanen
★★★★
......
Credit Score: Trustworthy
Reputation scores: 340
Date of birth: ......
Active relations 1
MGL RAAMATUPIDAMINE UÜ
History of right of representation?
Field
Professional Activities
Business age
10y
Beneficial country:
et
Merlyn Loime ... - ...
MGL Disaine OÜ ... - ...
2014
2015
2017
2018
2020
2021
2023
2024
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
MGL RAAMATUPIDAMINE UÜ
Owners?
Former owners
| Name | Credit Score | Payment | Beginning | Type | Holding |
|---|---|---|---|---|---|
| ...... |
MGL RAAMATUPIDAMINE UÜ
Subsidiaries and associates?
Former subsidiaries and associates
Finances and assets
MGL RAAMATUPIDAMINE UÜ
GoodwillMGL RAAMATUPIDAMINE UÜ
Paid taxes and estimated average salariesMGL RAAMATUPIDAMINE UÜ
Quarterly indicators| Quarter | Turnover | Taxed turnover | Labor productivity | Labor productivity | Employees | National taxes | Labor taxes |
|---|---|---|---|---|---|---|---|
| 2024 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2016 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2016 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2016 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2015 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2015 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
MGL RAAMATUPIDAMINE UÜ
Sales revenue by business areaMGL RAAMATUPIDAMINE UÜ
Sales revenue by countryMGL RAAMATUPIDAMINE UÜ
Financial indicators and prognosisMGL RAAMATUPIDAMINE UÜ
Financial raiting: "VERY GOOD" (2024 prognosis)2024 prognosis
LIQUIDITY
?
Net Working capital
...
Short-term debt coverage ratio
...
USE OF LOAN CAPITAL
?
Turnover ratio of fixed assets (X)
...
EFFECTIVENESS
?
Debt to assets ratio (X)
...
Capitalisation multiplier (X)
...
PROFITABILITY
?
Sales revenues (%)
...
Total asset revenues (%)
...
Equity revenues (%)
...
Unsatisfactory
1
2
3
4
5
Very good
MGL RAAMATUPIDAMINE UÜ
Annual reports| Year | Period | Submitted | Report PDF |
|---|---|---|---|
| 2023 | 01.01.2023–31.12.2023 | 21.05.2024 | ...... |
| 2022 | 01.01.2022–31.12.2022 | 19.05.2023 | ...... |
| 2021 | 01.01.2021–31.12.2021 | 19.07.2022 | ...... |
| 2020 | 01.01.2020–31.12.2020 | 29.06.2021 | ...... |
| 2019 | 01.01.2019–31.12.2019 | 22.04.2020 | ...... |
| 2018 | 01.01.2018–31.12.2018 | 03.06.2019 | ...... |
| 2017 | 01.01.2017–31.12.2017 | 26.06.2018 | ...... |
| 2016 | 01.01.2016–31.12.2016 | 20.02.2017 | ...... |
| 2015 | 01.01.2015–31.12.2015 | 26.02.2016 | ...... |
Liabilities and debts
MGL RAAMATUPIDAMINE UÜ
Credit score history and prognosisRecommended credit limit
... €
Recommended payment term
......
Business risk classes:
Trustworthy Neutral Borderline Problematic Risky
MGL RAAMATUPIDAMINE UÜ
Reports and assets-liabilities overview 25.11.2024?
Annual reports: ......
Annual reports: ......
Tax declarations:......
Assets to cover liabilities (short term)
Assets: ...... €1 EURO asset to cover short-term debt obligations: ...... €
Liabilities: ...... €Net Working capital: ...... €
MGL RAAMATUPIDAMINE UÜ
Claims history?
Debt claims as of ......
Total debt claims: ...... €
Latest events
| ...... | ...... |
MGL RAAMATUPIDAMINE UÜ
Income (turnover) and expenditure (taxes paid)?
| Quarter | Turnover | Taxed turnover | National taxes paid | Labor taxes paid | Number of employees |
|---|---|---|---|---|---|
| 2024 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 III | * ...... € | ...... € | ...... € | ...... € | ...... |
MGL RAAMATUPIDAMINE UÜ
Bailiff's enforcement proceedings as of 25.11.2024?
Bailiff's enforcement proceedings MISSING
MGL RAAMATUPIDAMINE UÜ
Regulations of the Payment Order Department as of 25.11.2024?
Regulations of the Payment Order Department MISSING
MGL RAAMATUPIDAMINE UÜ
Court orders in the register as of 25.11.2024?
Eitav kandemäärus: puudused kõrvaldamata
26.10.2023
Regulation number: Ä 10200346 / 7
Regulation status has entered into force: 26.10.2023
Määruse olek: Allkirjastatud
Puuduste kõrvaldamise määrus
04.10.2023
Regulation number: Ä 10200346 / M1
Regulation status has entered into force: 04.10.2023
Määruse olek: Allkirjastatud
MGL RAAMATUPIDAMINE UÜ
Decisions of the Consumer Disputes Committee as of 25.11.2024?
Consumer disputes MISSING
MGL RAAMATUPIDAMINE UÜ
Court hearings as of 25.11.2024?
Court hearings MISSING
MGL RAAMATUPIDAMINE UÜ
Rulings as of 25.11.2024?
Court settlemets MISSING
MGL RAAMATUPIDAMINE UÜ
Notices and announcements as of 25.11.2024?
Announcements MISSING
Marketing
Business network
MGL RAAMATUPIDAMINE UÜ
Business networkCREDIT RISK CLASSES
Deleted
Trustworthy
Neutral
Borderline
Problematic
Risky
Historical connection
Active connection
amount of turnover
amount of debt
Extension of networks
The network is visible with reduced links
Expand threads if desired
Beneficiaries network
MGL RAAMATUPIDAMINE UÜ
Networks - Beneficiaries The network is visible with reduced links
Expand threads if desired
Monitoring events
Filter
Dropdown
Dropdown
Neutral
Positive
Negative
No monitoring events were found
Failed to load monitoring events